SynOx Therapeutics

Description: SynOx Therapeutics develops emactuzumab, a monoclonal antibody for treating tenosynovial giant cell tumors (TGCT) and macrophage-driven diseases.

Country: Ireland

Based in: Dublin

Founded: 2020

Funding Stage: Series A/B

Tags: ['Biotechnology', 'Medical', 'Clinical Dta']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.